He developed immunotherapy toxicity, which prompted early discontinuation, but fortunately, due to a targetable B-raf mutation, his melanoma has a sustained complete response to B-raf and MEK dual oral targeted therapy with minimal long-term side effects. Here, MAP2K7 is linked to melanoma.